van Rossum Inge, Boomsma Maarten, Tenback Diederik, Reed Catherine, van Os Jim
Medical Department, Eli Lilly Nederland, Houten, The Netherlands.
J Nerv Ment Dis. 2009 Jan;197(1):35-40. doi: 10.1097/NMD.0b013e31819292a6.
Research suggests that cannabis use affects negatively on onset and outcome of schizophrenia, but less is known about possible effects in mood disorders. Bipolar in- and outpatients (N = 3459) were enrolled in an observational study. The influence of cannabis exposure on clinical and social treatment outcome measures was examined over the course of 1 year, as well as the effects on these associations of third mediating variables. Over 12 months of treatment, cannabis users exhibited less compliance and higher levels of overall illness severity, mania, and psychosis compared with nonusers. Additionally, cannabis users experienced less satisfaction with life and had a lower probability of having a relationship compared with nonusers. There was little evidence that cannabis-outcome associations were mediated by third variables. An independent impact of cannabis use on psychopathologic outcomes in patients with bipolar disorder was apparent, whereas the impact on social outcomes was modest.
研究表明，使用大麻会对精神分裂症的发病和预后产生负面影响，但对于其在情绪障碍中可能产生的影响了解较少。对3459名双相情感障碍门诊和住院患者进行了一项观察性研究。在1年的时间里，研究了大麻暴露对临床和社会治疗结果指标的影响，以及对这些关联的第三个中介变量的影响。在12个月的治疗过程中，与不使用大麻的患者相比，使用大麻的患者表现出更低的依从性，以及更高的总体疾病严重程度、躁狂和精神病水平。此外，与不使用大麻的患者相比，使用大麻的患者对生活的满意度较低，建立人际关系的可能性也较小。几乎没有证据表明大麻与结果之间的关联是由第三个变量介导的。大麻使用对双相情感障碍患者心理病理结果有明显的独立影响，而对社会结果的影响较小。
